

Product Data Sheet

Product Name: SC912
Cat. No.: GC73950

Chemical Properties

Cas. No.


Formula $C_{22}H_{13}Cl_2F_3N_4O_2$ M.Wt 493.27

Solubility DMSO : 100 mg/mL (202.73 mM; Storage -20°C
Need ultrasonic)

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

SC912 is an AR-V7 inhibitor ($IC_{50} = 0.36 \mu M$). SC912 possesses safety, potency and selectivity. SC912 binds directly to AR-FL and AR-V7 proteins, inhibits nuclear localization and chromatin binding capabilities. SC912 exerts anticancer activity through inhibition of proliferation, induction of cell cycle arrest and apoptosis.

SC912 (0.1-10 μM ; 24 h) effectively inhibits AR activation in PC3 Cells. No inhibition of GR and PR (AR $IC_{50} = 0.57 \mu M$)[1]. SC912 (0.03-100 μM ; 1 h) binding to AR-FL and AR-V7 is attenuated in 293 T

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

cells deleted for AR-NTD amino acids 507-531. Amino acids 507-531 are essential for the antagonistic activity[1]. SC912 (2 μ M; 24 h) strongly represses the transcription of AR-regulated genes (PSA, FKBP5, TMPRSS2) that are uniquely regulated by AR-V7 in the LNCaP95 cell model, suggesting effective repression of AR-V7-mediated transcriptional activity[1]. SC912 (1 μ M; 24 h) leads to G1 phase blockade and causes apoptosis in LNCaP, VCaP and 22Rv1 cells[1]. SC912 (3 μ M; 5 h) significantly reduces the intranuclear accumulation of AR-FL and AR-V7 in LNCaP and LNCaP-AR-V7 cells, suggesting that is able to effectively block the nuclear localization of AR-V7. SC912 also significantly reduces the binding of AR proteins to the chromatin[1].

SC912 (60 mg/kg; i.p.; 5 times days for 3 weeks) halts the growth of VCaP tumors effectively. No noticeable loss in body weight of the mice, indicating good tolerability at the administered dose[1]. SC912 (90 mg/kg; i.p.; 5 days a week for 3 weeks) alleviates tumor progression even in this highly castration-resistant 22Rv1 model[1].

References:

[1]. Qianhui Y et al. SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain Oncogene. 2024 Mar

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA